INS and diabetes mellitus: Sulphonylureas are still the second most used oral agent in developing countries and resource-restrained environments after metformin.41 Diabetes results in a progressive decline in β-cell function.42 Sulphonylureas lower blood glucose by stimulating β-cell function and secrete more endogenous insulin.